Clinical trial · Observational
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
NCT06608511CI-TRIAL-00112978active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma of Skin | Skin Basal Cell Carcinoma | ALIAS | 0.90 |
| Basal Cell Carcinoma of Skin, Site Unspecified | Skin Basal Cell Carcinoma | ALIAS | 0.85 |
| Cutaneous Squamous Cell Carcinoma (CSCC) | Skin Squamous Cell Carcinoma | ALIAS | 0.85 |
| Melanoma (Skin Cancer) | Melanoma | ONTOLOGY_EXACT | 0.85 |
| Merkel Cell Carcinoma of Skin | — | UNRESOLVED | — |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw for the laboratory assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Skin cancer
- description
- Participants with melanoma or non-melanoma skin cancer
- interventionNames
- Other: Blood draw for the laboratory assessment
Primary outcomes (9)
- measure
- Change in tumor-derived exosomes and progression free survival
- timeFrame
- Baseline to progression, up to 3 years
- description
- To investigate whether changes in tumor-derived exomes measured in serum could represent a potential prognostic biomarker, measured as progression free survival (the duration of time from Day 1 of treatment to time of progression based on clinical or radiographic grounds) or death as a results of any cause, whichever occurs first.
- measure
- Change in circulating tumor cells and progression free survival
- timeFrame
- Baseline to progression, up to 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years. * Participants must meet at least one of the following criteria: * Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. * A confirmed diagnosis of melanoma or non-melanoma skin cancer. Exclusion Criteria: * Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \<18), and UW employees that report to the investigator(s) or to study team members. * Not suitable for study participation due to other reasons at the discretion of the investigators.
References
Publications (0)
Data not yet available
No reference posted for this study.